Business Overview / Sources of Revenue

Exelixis is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes cancer medicines, primarily small‑molecule tyrosine kinase inhibitors such as **CABOMETYX** (cabozantinib tablets) for renal cell carcinoma and **COMETRIQ** (cabozantinib capsules) for medullary thyroid cancer.[1][2][3]

The company’s **core revenue** comes from U.S. product sales of CABOMETYX and COMETRIQ.[1][2] It also earns **collaboration and license revenue** from ex‑U.S. partners that co-develop and commercialize cabozantinib and other pipeline assets.[3][5]

Recent filings indicate revenue is **predominantly product-based**, with **the vast majority (roughly 80–90%) from cabozantinib franchise product sales** and the **remainder from collaboration, license, and milestone payments**; exact percentages vary year to year depending on milestone timing (inferred from segment discussions in company reports).[1][3][5]

Revenue Growth Potential and Recurrence

Exelixis’ revenue is **highly recurring**, with the vast majority coming from ongoing U.S. product sales of **Cabometyx/cabozantinib** in chronic oncology indications, supplemented by relatively smaller, lumpier collaboration revenue.[1][4][5]

In 2024, Exelixis generated about **$2.17B** in revenue, almost all from cabozantinib franchise sales plus collaborations.[5] In 2025, guidance is **$2.30–$2.35B**, implying low- to mid-single-digit growth off that base.[4] Cabometyx U.S. net product revenue has recently grown around **high teens YoY** (e.g., +19% in Q2 2025).[1] Over the next 5+ years, consensus and management commentary imply a transition from high-teens franchise growth toward **mid‑single‑ to low‑double‑digit annual revenue growth**, driven by further penetration/label expansions for cabozantinib and potential contributions from pipeline assets, partially offset by eventual maturity and competitive pressure.

Economic Moat Factors

Exelixis appears to have at most a **narrow, time‑limited moat**, and some analysts rate it **no‑moat**.[1][5]

Its main advantage is **intangible assets**: patents and regulatory exclusivity around cabozantinib/CABOMETYX, which generate high‑margin recurring revenue and fund R&D.[1][2] These protections expire in the early 2030s, after which generic TKIs can rapidly erode economics.[2][5]

Exelixis lacks meaningful **switching costs, network effects, or brand power**; oncologists readily switch to superior or cheaper therapies, and competition in renal and liver cancer is intense.[1][3] The business is **concentrated** in one franchise, with other pipeline assets not yet commercially validated, limiting diversification benefits.[1][3]

Scale helps fund trials but does not create a durable **economies‑of‑scale** barrier against larger oncology peers. Overall, moat quality depends heavily on replenishing patented assets before CABOMETYX exclusivity fades.

Leadership

Exelixis is led by **Michael M. Morrissey, Ph.D.**, President and CEO, who is **not a company founder** but an early executive (joined 2000) and became CEO in **2010**.[6] Public filings show he owns a **modest single‑digit percentage stake** (well under 5% of shares, mostly from equity awards).[5] The broader leadership team includes long‑tenured internal scientific executives, such as EVP R&D Dana T. Aftab, Ph.D., reflecting continuity and a research‑driven culture.[1][2][3][4]

Financial Health

Exelixis has a **very strong balance sheet**, with **no debt** and about **$0.99–1.4B in cash and short‑term investments**.[3][1] Its cash-to-debt ratio is therefore effectively infinite and clearly healthy.[3] The business is **consistently free‑cash‑flow positive**, with FCF margin roughly in the **high teens to low‑20s % range** based on recent profitability and reinvestment levels (inferred from TTM EBIT of ~$820M and strong cash build).[3][1] The company has been a **net share repurchaser**, buying back about **$302M (7.5M shares)** in Q2 2025 alone.[1]

Last updated Dec 7, 2025